NCT00863005View on ClinicalTrials.gov

Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Atopic Dermatitis
Interventions
DRUG

K201

Cream

DRUG

K201

Trial Locations (1)

Unknown

bioskin GmbH, Hamburg

Sponsors

Lead Sponsor

Moberg Pharma AB
All Listed Sponsors
lead

Moberg Pharma AB

INDUSTRY

NCT00863005 - Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study | Biotech Hunter | Biotech Hunter